IsoPet®
RadioGel™ | Yttrium-90 (Y-90) Precision Radionuclide Therapy (PRnT) for Veterinary Applications
Our IsoPet® division is focused on bringing RadioGel™ Yttrium-90 brachytherapy products to veterinary oncologists to treat dogs, cats and horses suffering from
cancerous tumors.
Initial treatments were coordinated through the Chair of the company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos. There are over 150 million pet dogs and cats, with over 1/3 of
the households in the US owning at least one dog, and just under 1/3 owning at least one cat.
Dr. Alice Villalobos stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of
companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as
IsoPet® (RadioGel™ Y-90) brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product
line for the treatment of accessible and inoperable tumors."
Our IsoPet® division is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product
awareness and education to veterinary oncologists.
CEO | President Mike Korenko stated: “IsoPet® allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that IsoPet® is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”
Learn more about IsoPet's® first companion animal treatments through a study at Washington State University funded by the Washington State Life Sciences Discovery Fund for the treatment of feline sarcoma.
IsoPet's Y-90 Precision Radionuclide Therapy (PRnT) device can be delivered into tumors on an out patient basis. I believe that veterinary oncologists around the globe finally have an ideal product for the treatment of accessible and inoperable tumors.
Dr. Alice Villalobos – Chair Veterinary Medical Advisory Board
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB:RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
